Kathleen N. Moore, MD, MS, FASCO, Deputy Director at the Stephenson Cancer Center in Oklahoma City, teams up with optometrists Aaron S. Gold, OD, FAAO, and Carlo J. Pelino, OD, FAAO, to discuss collaborative care and multidisciplinary strategies for managing ocular toxicities in patients with cancer who are being treated with antibody drug conjugates.
Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
Media formats available:
Details
Presenters
Target Audience
This certified continuing medical education activity is designed for optometrists and comprehensive ophthalmologists who care for patients with cancer who are administered ADCs.
Grantor Statement
This activity is supported by an unrestricted educational grant from AbbVie.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Recognize the ocular findings associated with ADCs for the treatment of certain cancers
- Perform the appropriate baseline and follow-up ophthalmic exams for patients receiving ADC therapy
- Formulate a treatment plan for effective management of ocular AEs associated with ADC treatment
- Collaborate with the oncology care team to mitigate ADC treatment-associated ocular AEs and ensure optimal treatment outcomes
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Sponsored by:
Evolve Medical Education LLC is a COPE-accredited administrator.This activity, COPE Activity Number 130620, is accredited by COPE for continuing education for optometrists. This course is approved for 1.0 hour of CE.Course #: 97656-PH
Activity #: 130620COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Faculty
Kathleen N. Moore, MD, MS, FASCO
Virginia Kerley Cade Chair
in Developmental Therapeutics
Deputy Director
Stephenson Cancer Center
University of Oklahoma
Oklahoma City, OK
Aaron Samuel Gold, OD, FAAO
Miami Ocular Oncology & Retina
Miami, FL
Carlo J. Pelino, OD, FAAO
Associate Professor
The Pennsylvania College of Optometry
Philadelphia, PADisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
Kathleen N. Moore, MD, MS, FASCO, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board/Consultant: Aadi, Astra Zeneca, AbbVie, Blueprint Pharma, BioNTech, Corcept, Caris, Daiichi-Sankyo, Duality, Eisai, Genentech/Roche, Glaxo SmithKline, Immunogen, Janssen, Lilly, Merck, Mersana, Novartis, Regeneron, Schrodinger, Takeda, Tubulis, VBL Therapeutics, Verastem, Zentalis, and Zymeworks. Grant/Research Support: Genentech/Roche, Merck, and PTC Therapeutics.
Aaron Samuel Gold, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Regeneron.
Carlo J. Pelino, OD, FAAO, has had no financial relationships or affiliations with ineligible companies.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or AbbVie.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Sarah H. Van Tassel, MD
Justin Schweitzer, OD, FAAO
Paul Petrakos, DO, MS
I. Paul Singh, MD
Justin Schweitzer, OD, FAAO
Sarah H. Van Tassel, MD
Paul Petrakos, DO, MS
I. Paul Singh, MD
